Universal Biosensors, Inc. (ASX:UBI – Get Free Report) insider Craig Coleman bought 1,421,293 shares of the stock in a transaction on Monday, May 27th. The stock was purchased at an average cost of A$0.11 ($0.07) per share, for a total transaction of A$156,342.23 ($104,228.15).
Craig Coleman also recently made the following trade(s):
- On Wednesday, May 8th, Craig Coleman 29,506,606 shares of Universal Biosensors stock.
- On Monday, March 25th, Craig Coleman 1,000,000 shares of Universal Biosensors stock.
Universal Biosensors Stock Performance
The company has a current ratio of 4.13, a quick ratio of 2.13 and a debt-to-equity ratio of 24.25.
About Universal Biosensors
Universal Biosensors, Inc, through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity.
Read More
- Five stocks we like better than Universal Biosensors
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Foot Locker’s Quarter Sends Doubters Running
- What is a SEC Filing?
- Costco Wholesale Can Hit New Highs; A Rebound Is Coming
- 3 Tickers Leading a Meme Stock Revival
- Chevron Eyes Hess, Exxon Resists: Here’s the Trade
Receive News & Ratings for Universal Biosensors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universal Biosensors and related companies with MarketBeat.com's FREE daily email newsletter.
